Is it safe to consume olive oil while taking clopidogrel and apixaban (Elequis) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Olive Oil with Clopidogrel and Apixaban: Safety Assessment

Consuming olive oil while taking clopidogrel and apixaban together is safe and does not increase bleeding risk, as dietary olive oil lacks the concentrated antiplatelet compounds found in supplements that could theoretically interact with antithrombotic therapy.

Critical Safety Context for Dual Antithrombotic Therapy

Your combination of clopidogrel (antiplatelet) and apixaban (anticoagulant) carries significant bleeding risk that requires careful management, regardless of olive oil consumption:

  • Dual antithrombotic therapy increases major bleeding events 3.4-fold compared to monotherapy, with bleeding requiring transfusion or surgical intervention being the primary concern 1
  • The combination of anticoagulant and antiplatelet therapy increases major extracranial bleeding with an odds ratio of 2.4 (95% CI: 1.4 to 4.1), meaning as few as 67 patients need treatment to cause 1 additional major bleeding event 1

Olive Oil Specifically: No Contraindication

Dietary olive oil does not pose bleeding risk concerns when consumed as part of normal food intake while on clopidogrel and apixaban. The theoretical bleeding concerns apply only to concentrated garlic supplements (not olive oil), which contain compounds that inhibit thromboxane synthetase and reduce platelet aggregation 1.

Verify Your Dual Therapy Indication

This combination should only be used in specific high-risk scenarios such as atrial fibrillation patients with recent coronary stenting 1. The evidence shows:

  • Dual therapy (anticoagulant + single antiplatelet) is effective and associated with less bleeding risk than triple therapy in patients with atrial fibrillation undergoing PCI with stent placement 2
  • Apixaban combined with clopidogrel showed no efficacy benefit but increased bleeding in post-acute coronary syndrome patients, with Thrombolysis In Myocardial Infarction major bleeding increasing from 1.02 to 2.58 per 100 patient-years 3

Mandatory Gastrointestinal Protection

You must be prescribed a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding risk 1, 4:

  • Pantoprazole, dexlansoprazole, or lansoprazole are the preferred PPIs because they have minimal CYP450 2C19 inhibition and won't interfere with clopidogrel's effectiveness 5, 1
  • Avoid omeprazole, which has the strongest evidence for reducing clopidogrel's antiplatelet effect through CYP2C19 inhibition 1, 4

High-Risk Features Requiring Close Monitoring

Monitor closely if you have any of these characteristics 1:

  • Age over 75 years
  • History of gastrointestinal bleeding or peptic ulcer disease
  • Renal impairment
  • Body weight <60 kg

Foods and Supplements to Avoid

While olive oil is safe, discontinue any concentrated herbal supplements, particularly:

  • Garlic supplements (not dietary garlic in food) pose theoretical increased bleeding risk when combined with dual antithrombotic therapy 1
  • Ashwagandha should be discontinued immediately if currently taking it with clopidogrel and apixaban 1

Duration and Transition Strategy

Current guidelines recommend 2:

  • Dual therapy should be continued for 12 months after coronary stenting
  • Oral anticoagulant monotherapy (apixaban alone) should be continued thereafter
  • Aspirin should be discontinued at discharge in most patients to reduce bleeding risk

Alternative Considerations

Depending on your specific indication 1:

  • Apixaban monotherapy may be sufficient for stroke prevention in atrial fibrillation without adding clopidogrel
  • Clopidogrel monotherapy may be appropriate for coronary artery disease without atrial fibrillation

References

Guideline

Bleeding Risk Management in Patients on Dual Antithrombotic Therapy with Garlic Supplement Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019

Guideline

Dual Antiplatelet Therapy with Clopidogrel and Aspirin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Medication-Related Risk of Gastrointestinal Bleeding

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.